Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315848 · ClinicalTrials.gov registry record · Phase 3
The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.
A Phase 3 study of Osteoarthritis, sponsored by Purdue Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
- 10
- Study locations
NCT00315848 is a Phase 3 study of Osteoarthritis that has completed, run by Purdue Pharma. The registered enrollment target is 225 participants, below the 816-participant average among 135 other Osteoarthritis trials with a reported enrollment target (72% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT00315848, a Phase 3 study of Osteoarthritis, has completed, sponsored by Purdue Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
- 10
- Study locations
Study Summary
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system and immediate release oxycodone/acetaminophen in subjects with osteoarthritis pain inadequately treated with non-opioid analgesics. The double-blind treatment intervention duration is 60 days.
Conditions Studied
Interventions
- DRUG Buprenorphine transdermal delivery system
Study Locations (10)
Arizona
- Arizona Research and Education - Phoenix
- Phoenix Center for Clinical Research - Phoenix
Florida
- Gainesville Clinical Research Center - Gainesville
- Park Place Therapeutic Center - Plantation
Texas
- Metroplex Clinical Research Center - Dallas
- Arthritis Diagnostic and Treatment Center - San Antonio
Alabama
- Rheumatology Associates of North Alabama - Huntsville
Colorado
- Western Integrated Pain Treatment Centers - Westminster
Indiana
- MediSphere Medical Research Center, L.L.C. - Evansville
New York
- Stratton VA Medical Center - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 1996-11 |
| Est. Completion | 1999-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00315848
The ClinicalTrials.gov registry entry for NCT00315848 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 816-participant average among 135 other Osteoarthritis trials with a reported enrollment target (72% lower). The listed sponsor is Purdue Pharma, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine transdermal delivery system is the first listed.
NCT00315848 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Arizona, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT00315848 about?
NCT00315848 is a clinical study titled "The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.". The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system and immediate release oxycodone/acetaminophen in subjects with osteoarthritis pain inadequately treated with non-opi...
What is the current status of trial NCT00315848?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 1996-11. Estimated completion is 1999-12.
What conditions does trial NCT00315848 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT00315848?
The interventions under investigation include: Buprenorphine transdermal delivery system (DRUG).
Who is sponsoring clinical trial NCT00315848?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00315848 being conducted?
This trial has 10 study locations across Alabama, Arizona, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Beat Pain Better Trial
RECRUITING · Phase 3
-
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
RECRUITING · Phase 3
-
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
COMPLETED · Phase 3
-
Allograft Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe
COMPLETED · Phase 3
-
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.